Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2018 - Product Image

Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2018

  • ID: 4576130
  • Report
  • 36 pages
  • Global Markets Direct
1 of 4
Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2018

Summary:

According to the recently published report 'Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2018'; Cell Division Protein FtsZ (ftsz) pipeline Target constitutes close to 9 molecules. Out of which approximately 2 molecules are developed by companies and remaining by the universities/institutes.

Cell Division Protein FtsZ (ftsz) -

The report 'Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2018' outlays comprehensive information on the Cell Division Protein FtsZ (ftsz) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 5 molecules, respectively.

Report covers products from therapy areas Infectious Disease which include indications Escherichia coli Infections, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Tuberculosis, Bacillus Infections, Enterococcus faecium Infections, Skin And Skin Structure Infections (SSSI) Caused By Bacteria, Staphylococcus aureus Infections, Streptococcal Pneumonia and Vancomycin-Resistant Enterococcus faecium Infections.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Cell Division Protein FtsZ (ftsz)
  • The report reviews Cell Division Protein FtsZ (ftsz) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cell Division Protein FtsZ (ftsz) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cell Division Protein FtsZ (ftsz) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cell Division Protein FtsZ (ftsz) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cell Division Protein FtsZ (ftsz)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cell Division Protein FtsZ (ftsz) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Introduction

Report Coverage

Cell Division Protein FtsZ (ftsz) - Overview

Cell Division Protein FtsZ (ftsz) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cell Division Protein FtsZ (ftsz) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cell Division Protein FtsZ (ftsz) - Companies Involved in Therapeutics Development

TAXIS Pharmaceuticals Inc

Cell Division Protein FtsZ (ftsz) - Drug Profiles

BIZ-20131 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIZ-20132 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIZ-20133 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

chrysophaentin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SBP-17GA20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit FtsZ for Streptococcal Pneumonia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit FtsZ for Tuberculosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TXA-497 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TXA-709 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cell Division Protein FtsZ (ftsz) - Dormant Products

Cell Division Protein FtsZ (ftsz) - Product Development Milestones

Featured News & Press Releases

Sep 07, 2016: FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic:

Jun 13, 2016: Experimental Antibiotic Treats Deadly MRSA Infection

Sep 18, 2015: TAXIS Pharmaceuticals Demonstrates Synergistic Efficacy Against MRSA And Low Resistance Frequency With TXA709/Cefdinir Combination

Jun 05, 2015: TAXIS Pharmaceuticals Announces Publication of Data Demonstrating Potential Viability of TXA709 in Combating Antibiotic Resistance

Apr 27, 2015: TAXIS Pharmaceuticals Demonstrates Clinical Potential of TXA709 in Combating Antibiotic Resistance

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by TAXIS Pharmaceuticals Inc, H1 2018

Dormant Projects, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • TAXIS Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll